Thomas C. Merigan

Thomas C. Merigan's AcademicInfluence.com Rankings

Thomas C. Merigan

Biology

#3897

World Rank

#5895

Historical Rank

Virology

#75

World Rank

#78

Historical Rank

biology Degrees

Download Badge

Biology

Thomas C. Merigan's Degrees

PhD Virology University of California, Berkeley
Doctorate Medicine University of California, San Francisco

Why Is Thomas C. Merigan Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Thomas Charles Merigan was born January 18, 1934 in San Francisco. He is an American virologist and the George E. and Lucy Becker Professor of Medicine, Emeritus at the Stanford University School of Medicine. Merigan's research first focused on human viral pathogenesis, basic and clinical studies of interferon, and then developing the first systemically active antiviral drugs including those effectively treatIng HIV/AIDS, several herpesviruses and hepatitis B. He is also credited with helping to develop the use of interferons as antiviral, immunomodulating and antitumor therapies. Merigan joined the Stanford faculty in 1963 and assumed full emeritus status in 2007. In 2004 he was also identified as one of the 250 most cited investigators in clinical medicine over the last 20 years by the Institute for Scientific Information. Merigan also was ranked 23rd among the 1000 top US microbiologists by Research.com in 2022. His papers have been cited over 45,000 times. He had over 95 postdoctoral fellows, students and visiting scientists with whom he published 577 papers, 24 books monographs and published symposia, and held 11 US patents. Two of his books went into multiple editions- one into a 4th edition and the other into a 3rd. His students have become leaders in the fields of infectious diseases and microbiology both in the US and the world. Seven of his students subsequently joined the Stanford medical faculty. He was a board member of 28 journals and a member of 23 learned societies. He told his life story in a book entitled Pioneering Viral Therapy,a Life in Academic Medicine, published by Amazon/Kindle/CreateSpace in 2017.

(See a Problem?)

Thomas C. Merigan's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team. (1996) (1011)
Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group. (1996) (739)
Extensive polymorphisms observed in HIV–1 clade B protease gene using high–density oligonucleotide arrays (1996) (559)
Recombinant interferon-gamma increases HLA-DR synthesis and expression. (1983) (557)
A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy (2000) (543)
The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection a double-blind, placebo-controlled trial (1990) (532)
The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team. (1996) (502)
Effect of human leukocyte interferon on hepatitis B virus infection in patients with chronic active hepatitis. (1976) (481)
Recombinant leukocyte A interferon: pharmacokinetics, single-dose tolerance, and biologic effects in cancer patients. (1982) (378)
Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. (2003) (357)
A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation. (1992) (351)
Recombinant gamma interferon induces HLA-DR expression on cultured human keratinocytes. (1984) (337)
The Effect of High-Dose Saquinavir on Viral Load and CD4+ T-Cell Counts in HIV-Infected Patients (1996) (306)
A randomized controlled trial of a reduced daily dose of zidovudine in patients with the acquired immunodeficiency syndrome (1990) (303)
Frequency of class I HLA-restricted anti-HIV CD8+ T cells in individuals receiving highly active antiretroviral therapy (HAART). (1999) (298)
Impact of prophylactic immediate posttransplant ganciclovir on development of transplant atherosclerosis: a post hoc analysis of a randomized, placebo-controlled study. (1999) (287)
Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group Study. (2005) (271)
Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34+ cells. (2009) (252)
Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection. (2003) (252)
Survival in chronic hepatitis B. An analysis of 379 patients. (1984) (251)
Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy (1996) (248)
Inhibition of respiratory virus infection by locally applied interferon. (1973) (243)
Evolution of recurrent herpes simplex lesions. An immunohistologic study. (1985) (243)
Effects of immunosuppressive therapy on viral markers in chronic active hepatitis B. (1981) (237)
HIV-1 Genotypic Resistance Patterns Predict Response to saquinavirritonavir Therapy in Patients in Whom Previous Protease Inhibitor Therapy Had Failed (1999) (231)
A 6-basepair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors. (1998) (228)
Patient compliance and drug failure in protease inhibitor monotherapy. (1996) (215)
Rapid detection and quantitation of human cytomegalovirus in urine through DNA hybridization. (1983) (212)
Increased pulmonary superinfections in cardiac-transplant patients undergoing primary cytomegalovirus infection. (1978) (212)
Cytomegalovirus immune plasma in bone marrow transplant recipients. (1982) (208)
Antiviral treatment of chronic hepatitis B virus infection. I. Changes in viral markers with interferon combined with adenine arabinoside. (1981) (207)
Textbook of AIDS Medicine (1994) (205)
Treatment of B-cell lymphomas with anti-idiotype antibodies alone and in combination with alpha interferon. (1989) (204)
Multiple Concurrent Reverse Transcriptase and Protease Mutations and Multidrug Resistance of HIV-1 Isolates from Heavily Treated Patients (1998) (204)
Herpes Zoster-Varicella infections and lymphoma. (1972) (202)
Concerning the mechanism of action of interferon. (1966) (201)
Human cytomegalovirus strain Towne glycoprotein B is processed by proteolytic cleavage. (1988) (200)
Inhibition of human immunodeficiency virus gene amplification by heparin (1991) (197)
Circulating p24 antigen levels and responses to dideoxycytidine in human immunodeficiency virus (HIV) infections. A phase I and II study. (1989) (196)
Cytomegalovirus retinitis in immunosuppressed hosts. II. Ocular manifestations. (1980) (182)
Effect of Baseline- and Treatment-Related Factors on Immunologic Recovery After Initiation of Antiretroviral Therapy in HIV-1-Positive Subjects: Results From ACTG 384 (2006) (178)
Interferon: Immunobiology and Clinical Significance (1982) (169)
Recombinant soluble CD4 therapy in patients with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. A phase I-II escalating dosage trial. (1990) (167)
Cellular immunity and herpesvirus infections in cardiac-transplant patients. (1977) (164)
Role of G0-G1 arrest in the inhibition of tumor cell growth by interferon. (1980) (164)
Detection of human immunodeficiency virus DNA and RNA in semen by the polymerase chain reaction. (1991) (161)
Absent or rare human immunodeficiency virus infection of bone marrow stem/progenitor cells in vivo (1991) (154)
Human immunodeficiency virus type 1 reverse transcriptase genotype and drug susceptibility changes in infected individuals receiving dideoxyinosine monotherapy for 1 to 2 years (1997) (154)
Human leukocyte interferon for the treatment of varicella in children with cancer. (1982) (151)
Adverse effect of cytosine arabinoside on disseminated zoster in a controlled trial. (1973) (149)
2',3'‐Dideoxycytidine (ddC) toxic neuropathy (1993) (149)
The immunosuppressive effect of type II mouse interferon preparations on antibody production. (1977) (149)
Virus-specific IgG and IgM antibodies in normal and immunocompromised subjects infected with cytomegalovirus. (1982) (146)
Induction and kinetics of natural killer cells in humans following interferon therapy (1979) (142)
A mutation in human immunodeficiency virus reverse transcriptase and decline in CD4 lymphocyte numbers in long-term zidovudine recipients. (1993) (139)
Detection and Qualification of Human Immunodeficiency Virus RNA in Patient Serum by Use of the Polymerase Chain Reaction (1991) (138)
Lymphocyte interferon production and transformation after Herpes simplex infections in humans. (1974) (138)
Infections due to herpesviruses in cardiac transplant recipients: role of the donor heart and immunosuppressive therapy. (1983) (135)
The interaction of human macrophages and lymphocytes in the phytohemagglutinin-stimulated production of interferon. (1971) (133)
Murine monoclonal antibody to a single protein neutralizes the infectivity of human cytomegalovirus. (1984) (132)
Characteristics of immune interferon produced by human lymphocyte cultures compared to other human interferons. (1975) (131)
Highly drug-resistant HIV-1 clinical isolates are cross-resistant to many antiretroviral compounds in current clinical development. (1999) (131)
Antiviral activity of lamivudine in salvage therapy for multidrug-resistant HIV-1 infection. (2005) (128)
Systemic alpha‐interferon therapy of multiple sclerosis (1984) (127)
Short-term safety and antiretroviral activity of T-1249, a second-generation fusion inhibitor of HIV. (2004) (126)
Induction of Circulating Interferon by Synthetic Anionic Polymers of Known Composition (1967) (120)
Interferon-stimulating and in vivo antiviral effects of various synthetic anionic polymers. (1968) (117)
Cytomegalovirus retinitis in immunosuppressed hosts. I. Natural history and effects of treatment with adenine arabinoside. (1980) (117)
Follow-up observations on the effect of human leukocyte interferon in non-Hodgkin's lymphoma. (1981) (116)
Administration of human leukocyte interferon in herpes zoster. I. Safety, circulating, antiviral activity, and host responses to infection. (1974) (115)
Antiproliferative effects of recombinant alpha- and gamma-interferons on cultured human keratinocytes. (1984) (115)
Mechanism of the suppressive effect of interferon on antibody synthesis in vivo. (1975) (115)
Effect of vidarabine on chronic hepatitis B virus infection. (1978) (114)
Antiviral Agents and Viral Diseases of Man (1990) (114)
Persistence of attenuated rev genes in a human immunodeficiency virus type 1-infected asymptomatic individual (1995) (113)
Interferon acts directly on human B lymphocytes to modulate immunoglobulin synthesis. (1981) (112)
Cellular and humoral immunity in the pathogenesis of recurrent herpes viral infections in patients with lymphoma. (1980) (111)
Interferon increases HLA synthesis in melanoma cells: interferon-resistant and -sensitive cell lines. (1982) (111)
Interferon Induction Increased through Chemical Modification of a Synthetic Polyribonucleotide (1969) (110)
Recombinant gamma interferon differentially regulates class II antigen expression and biosynthesis on cultured normal human keratinocytes. (1985) (109)
Recombinant interleukin 2 as an adjuvant for vaccine-induced protection. Immunization of guinea pigs with herpes simplex virus subunit vaccines. (1988) (108)
Human Immunodeficiency Virus Type 1 Protease Genotypes and In Vitro Protease Inhibitor Susceptibilities of Isolates from Individuals Who Were Switched to Other Protease Inhibitors after Long-Term Saquinavir Treatment (1998) (107)
Antibody response to human cytomegalovirus glycoproteins gB and gH after natural infection in humans. (1991) (107)
Drug Resistance and Heterogeneous Long-Term Virologic Responses of Human Immunodeficiency Virus Type 1-Infected Subjects to Zidovudine and Didanosine Combination Therapy (1995) (107)
Collaborative phase I-II study of recombinant DNA-produced leukocyte interferon (clone A) in metastatic breast cancer, malignant lymphoma, and multiple myeloma. (1984) (106)
CIRCULATING INTERFERON AFTER MEASLES VACCINATION. (1965) (104)
A pilot clinical trial of HIV antigen-pulsed allogeneic and autologous dendritic cell therapy in HIV-infected patients. (1998) (103)
Interferon, antibody, and other host factors in herpes zoster. (1972) (102)
Viral polypeptides detected by a complement-dependent neutralizing murine monoclonal antibody to human cytomegalovirus (1985) (101)
Interferon induction in man by a synthetic polyanion of defined composition. (1967) (101)
Human interferon alpha in malignant lymphoma and Hodgkin's disease. Results of the american cancer society trial (1985) (97)
"Wide-open" 1.3 A structure of a multidrug-resistant HIV-1 protease as a drug target. (2005) (96)
Didanosine Resistance in HIV-infected Patients Switched from Zidovudine to Didanosine Monotherapy (1994) (93)
Time and dosage dependence of immunoenhancement by murine type II interferon preparations. (1978) (92)
gamma Interferon production appears to predict time of recurrence of herpes labialis. (1983) (92)
Selective impairment of lymphocyte reactivity to varicella-zoster virus antigen among untreated patients with lymphoma. (1978) (92)
Effect of leukocyte interferon on urinary excretion of cytomegalovirus by infants. (1976) (91)
Antiviral treatment of chronic hepatitis B virus infection: Improvement in liver disease with interferon and adenine arabinoside (1981) (90)
Suppressive effect of interferon on the humoral immune response to sheep red blood cells in mice. (1974) (88)
Detection of human immunodeficiency virus type 1 in semen: effects of disease stage and nucleoside therapy. (1993) (88)
Cytomegalovirus gB genotype distribution differs in human immunodeficiency virus-infected patients and immunocompromised allograft recipients. (1997) (87)
Crystal Structures of a Multidrug-Resistant Human Immunodeficiency Virus Type 1 Protease Reveal an Expanded Active-Site Cavity (2004) (86)
Human keratinocyte-lymphocyte reactions in vitro. (1986) (84)
ACTION OF ENDOGENOUS INTERFERON AGAINST VACCINIA INFECTION IN CHILDREN. (1965) (84)
Cell-mediated immunity of cytomegalovirus infection in normal subjects and cardiac transplant patients. (1978) (84)
Human cytomegalovirus (CMV) DNA in plasma reflects quantity of CMV DNA present in leukocytes (1995) (83)
Identification of cell surface receptors for the 86-kilodalton glycoprotein of human cytomegalovirus. (1989) (83)
CONTROLLED CLINICAL TRIAL OF INTRAVENOUS ACYCLOVIR IN HEART-TRANSPLANT PATIENTS WITH MUCOCUTANEOUS HERPES SIMPLEX INFECTIONS (1981) (82)
Cutaneous interferon production in patients with Hodgkin's disease and other cancers infected with varicella or vaccinia. (1970) (82)
Purified Interferons: Physical Properties and Species Specificity (1964) (80)
Pharmacokinetics of rifabutin (1989) (79)
PPD-stimulated interferon: in vitro macrophage-lymphocyte interaction in the production of a mediator of cellular immunity. (1971) (79)
Biological variation and quality control of plasma human immunodeficiency virus type 1 RNA quantitation by reverse transcriptase polymerase chain reaction (1993) (79)
Immune specific production of interferon by human T cells in combined macrophage-lymphocyte cultures in response to Herpes simplex antigen. (1975) (78)
Reduction in plasma human immunodeficiency virus ribonucleic acid after dideoxynucleoside therapy as determined by the polymerase chain reaction. (1991) (78)
Physical properties of human interferon prepared in vitro and in vivo. (1966) (78)
Prolonged herpes-zoster infection associated with immunosuppressive therapy. (1979) (77)
Clinical and immunologic effects of recombinant leukocyte A interferon in eight patients with advanced cancer. (1982) (76)
Multilocus genetic interactions and response to efavirenz-containing regimens: an Adult AIDS Clinical Trials Group study (2006) (75)
Antiviral treatment of chronic hepatitis B virus infection: pharmacokinetics and side effects of interferon and adenine arabinoside alone and in combination (1982) (75)
High Degree of Interlaboratory Reproducibility of Human Immunodeficiency Virus Type 1 Protease and Reverse Transcriptase Sequencing of Plasma Samples from Heavily Treated Patients (2001) (74)
Natural killing in estrogen-treated mice responds poorly to poly I.C despite normal stimulation of circulating interferon. (1979) (73)
Prophylactic ganciclovir treatment reduces fungal as well as cytomegalovirus infections after heart transplantation. (1995) (72)
Current concepts of interferon and interferon induction. (1970) (71)
Selective increase in lymphocyte interferon response to vaccinia antigen after revaccination. (1972) (71)
Changes in CD4+ and CD8+ T cell subsets in response to highly active antiretroviral therapy in HIV type 1-infected patients with prior protease inhibitor experience. (1998) (71)
Absence of detectable IgM antibody during cytomegalovirus disease in patients with AIDS. (1983) (70)
Human Leukocyte Interferon in the Treatment of Varicella in Children with Cancer: a Preliminary Controlled Trial (1978) (69)
Interferon and Cytomegalovirus in vivo and in vitro.∗ (1967) (69)
Detection of drug resistance mutations in the human immunodeficiency virus type 1 (HIV-1) pol gene: differences in semen and blood HIV-1 RNA and proviral DNA. (1994) (69)
Purification and characterization of vertebrate interferons (1965) (68)
In vitro production and cellular origin of murine type II interferon. (1979) (67)
Synthetic Polyanions protect Mice against Intracellular Bacterial Infection (1970) (66)
Sequence and drug susceptibility of subtype C reverse transcriptase from human immunodeficiency virus type 1 seroconverters in Zimbabwe (1997) (66)
Lymphocyte transformation and interferon production in human mononuclear cell microcultures for assay of cellular immunity to herpes simplex virus (1976) (66)
Cell interaction with a synthetic polynucleotide and interferon production in vitro. (1969) (65)
Leu-3+ T cells produce gamma-interferon in patients with recurrent herpes labialis. (1984) (65)
Antigen-presenting liposomes are effective in treatment of recurrent herpes simplex virus genitalis in guinea pigs (1989) (64)
Phase I evaluation of a synthetic mutant of β-interferon (1985) (63)
Treatment of NZB/NZW F1 hybrid mice with Mycobacterium bovis strain BCG or type II interferon preparations accelerates autoimmune disease. (1981) (63)
Viral infections in man associated with acquired immunological deficiency states. (1971) (61)
Characterization of two different human cytomegalovirus glycoproteins which are targets for virus neutralizing antibody. (1988) (59)
The human cytomegalovirus strain Towne glycoprotein H gene encodes glycoprotein p86. (1989) (59)
Specific cell-mediated immunity and infections with herpes viruses in cardiac transplant recipients. (1982) (58)
Zidovudine Compared With Didanosine in Patients With Advanced HIV Type I Infection and Little or No Previous Experience With Zidovudine (1995) (58)
Significance of Local γ Interferon in Recurrent Herpes Simplex Infection (1986) (58)
Regulation of expression of class II major histocompatibility antigens on human peripheral blood monocytes and Langerhans cells by interferon. (1984) (57)
Clinical resistance patterns and responses to two sequential protease inhibitor regimens in saquinavir and reverse transcriptase inhibitor-experienced persons. (1999) (57)
Quantitation Of Human Cytomegalovirus DNA From Peripheral Blood Cells Of Human Immunodeficiency Virus-Infected Patients Could Predict Cytomegalovirus Retinitis (1995) (56)
Growth regulation of melanoma cells by interferon and (2'-5')oligoadenylate synthetase (1983) (56)
Suppressive effect of interferon on erythroid cell proliferation. (1979) (56)
Toxicity of vidarabine. (1979) (56)
Cellular events in zoster vesicles: relation to clinical course and immune parameters. (1975) (56)
Cytomegalovirus infection and abnormal T-lymphocyte subset ratios in homosexual men. (1985) (56)
Geographic and demographic differences in the frequency of human cytomegalovirus gB genotypes 1-4 in immunocompromised patients. (1998) (55)
Comparison of QIAamp HCV kit spin columns, silica beads, and phenol-chloroform for recovering human immunodeficiency virus type 1 RNA from plasma (1997) (55)
Detection and quantification of human immunodeficiency virus RNA in patient serum by use of the polymerase chain reaction. (1991) (55)
STRUCTURAL REQUIREMENTS FOR SYNTHETIC POLYANIONS TO ACT AS INTERFERON INDUCERS * (1970) (54)
Alternating and Intermittent Regimens of Zidovudine and Dideoxycytidine in Patients with AIDS or AIDS-Related Complex (1993) (54)
Topical interferon for treating condyloma acuminata in women. (1988) (54)
Effect of type I and type II interferons on murine thymocyte surface antigen expression: induction or selection? (1981) (54)
Acute Dane particle suppression with recombinant leukocyte A interferon in chronic hepatitis B virus infection. (1983) (53)
Multiple cerebral lesions complicating therapy with interleukin-2 (1996) (53)
Enhancement of human immunodeficiency virus (HIV)-specific CD4+ and CD8+ cytotoxic T-lymphocyte activities in HIV-infected asymptomatic patients given recombinant gp160 vaccine. (1992) (52)
Cell-mediated immunity to varicella-zoster virus: in vitro lymphocyte responses. (1974) (52)
Clinical cross-resistance between the HIV-1 protease inhibitors saquinavir and indinavir and correlations with genotypic mutations. (1999) (52)
Liposome-formulated interleukin-2 as an adjuvant of recombinant HSV glycoprotein gD for the treatment of recurrent genital HSV-2 in guinea-pigs. (1992) (51)
Bis-DEAE-fluorenone: mechanism of antiviral protection and stimulation of interferon production in the mouse. (1971) (50)
The tolerability and pharmacokinetics of N-butyl-deoxynojirimycin in patients with advanced HIV disease (ACTG 100). The AIDS Clinical Trials Group (ACTG) of the National Institute of Allergy and Infectious Diseases. (1995) (50)
Ganciclovir treatment of serious cytomegalovirus infection in heart and heart-lung transplant recipients. (1988) (49)
Frequency of Antiretroviral Drug Resistance Mutations in HIV-1 Strains from Patients Failing Triple Drug Regimens (2000) (49)
The antiviral activity of thiophosphate-substituted polyribonucleotides in vitro and in vivo. (1970) (49)
Role of T lymphocytes in cellular immune responses during herpes simplex virus infection in humans. (1978) (48)
Placebo-controlled trial to evaluate zidovudine in treatment of human immunodeficiency virus infection in asymptomatic patients with hemophilia. NHF-ACTG 036 Study Group. (1991) (48)
A randomized, placebo-controlled study of the immunogenicity of human immunodeficiency virus (HIV) rgp160 vaccine in HIV-infected subjects with > or = 400/mm3 CD4 T lymphocytes (AIDS Clinical Trials Group Protocol 137). (1996) (48)
Characterization of HLA-A 0201-restricted cytotoxic T cell epitopes in conserved regions of the HIV type 1 gp160 protein. (1995) (48)
Quantitation of human cytomegalovirus DNA from peripheral blood cells of human immunodeficiency virus-infected patients could predict cytomegalovirus retinitis. (1995) (47)
Human cytomegalovirus polypeptides stimulate neutralizing antibody in vivo. (1985) (46)
Moloney Sarcoma Virus-Induced Tumors in Mice: Inhibition or Stimulation by (Poly rI)·(Poly rC) 1 (1971) (46)
Two double-blinded, randomized, comparative trials of 4 human immunodeficiency virus type 1 (HIV-1) envelope vaccines in HIV-1-infected individuals across a spectrum of disease severity: AIDS Clinical Trials Groups 209 and 214. (2000) (46)
Vidarabine monophosphate and human leukocyte interferon in chronic hepatitis B infection. (1982) (46)
Thermal activation of the antiviral activity of synthetic double-stranded polyribonucleotides. (1971) (46)
Decrease in HIV provirus in peripheral blood mononuclear cells during zidovudine and human rIL-2 administration. (1992) (45)
Antiviral Treatment of Chronic Hepatitis B Virus Infection: Infectious Virus Cannot Be Detected in Patient Serum after Permanent Responses to Treatment (2007) (44)
Safety and efficacy of polyethylene glycol-modified interleukin-2 and zidovudine in human immunodeficiency virus type 1 infection: a phase I/II study. (1993) (44)
Immunomodulatory and antiproliferative effect of recombinant alpha, beta, and gamma interferons on cultured human malignant squamous cell lines, SCL-1 and SW-1271. (1985) (44)
Increase in Antiviral Activity of Polynucleotides by Thermal Activation (1970) (44)
Insertions in the Human Immunodeficiency Virus Type 1 Protease and Reverse Transcriptase Genes: Clinical Impact and Molecular Mechanisms (2005) (44)
Human leukocyte interferon administration to patients with symptomatic and suspected rabies (1984) (44)
Syngeneic monoclonal anti-idiotype antibodies that bear the internal image of a human cytomegalovirus neutralization epitope. (1988) (43)
Local and systemic protection by synthetic polyanionic interferon inducers in mice against intranasal, vesicular stomatitis virus. (1969) (43)
Synergistic antitumor effect of interferon and anti-idiotype monoclonal antibody in murine lymphoma. (1986) (42)
Short-course human leukocyte interferon in treatment of herpes zoster in patients with cancer (1981) (42)
The role of interferon in the protective effect of a synthetic double-stranded polyribonucleotide against intranasal vesicular stomatitis virus challenge in mice. (1970) (41)
β Interferon Produced by Keratinocytes in Human Cutaneous Infection with Herpes Simplex Virus (1987) (41)
A PLAQUE INHIBITION ASSAY FOR HUMAN INTERFERON EMPLOYING HUMAN NEONATE SKIN FIBROBLAST MONOLAYERS AND BOVINE VESICULAR STOMATITIS VIRUS (1971) (41)
Measurement of HIV virus load and genotypic resistance by gene amplification in asymptomatic subjects treated with combination therapy. (1993) (40)
Preliminary observation of hepatitis b‐associated membranous glomerulonephritis treated with leukocyte interferon (1985) (39)
A Useful Quantitative Semimicromethod for Viral Plaque Assay (1973) (39)
HIV-1 reverse transcriptase codon 215 mutation in plasma RNA: immunologic and virologic responses to zidovudine. The AIDS Clinical Trials Group Study 175 Virology Team. (1998) (39)
Safety and tolerance of dideoxycytidine as a single agent: Results of early-phase studies in patients with acquired immunodeficiency syndrome (AIDS) or advanced AIDS-related complex (1990) (39)
Regulatory Functions of Interferons (1980) (39)
Quantification and comparison of HIV-1 proviral load in peripheral blood mononuclear cells and isolated CD4+ T cells. (1993) (39)
Cervical intraepithelial neoplasia treated by perilesional injection of interferon (1986) (39)
Risk for retinitis in patients with AIDS can be assessed by quantitation of threshold levels of cytomegalovirus DNA burden in blood. (1997) (39)
Variants Other than Aspartic Acid at Codon 69 of the Human Immunodeficiency Virus Type 1 Reverse Transcriptase Gene Affect Susceptibility to Nucleoside Analogs (2001) (37)
Treatment of nasopharyngeal carcinoma with human leukocyte interferon. (1985) (36)
Diurnal and short-term stability of HIV virus load as measured by gene amplification. (1994) (36)
Alpha-interferon administration in cytomegalovirus retinitis (1984) (36)
Pharmacokinetics and side effects of interferon in man. (1977) (36)
Interferon inhibition of lymphocyte mitogenesis. (1977) (36)
Inhibition of human cytomegalovirus replication by 9-(1,3-dihydroxy-2-propoxymethyl)guanine alone and in combination with human interferons (1984) (36)
HIV-1 syncytium-inducing phenotype, virus burden, codon 215 reverse transcriptase mutation and CD4 cell decline in zidovudine-treated patients. (1994) (36)
Zoster immune globulin prophylaxis of disseminated zoster in compromised hosts. A randomized trial. (1980) (35)
The effect of interferon and interferon inducers on avian influenza. (1971) (35)
Interferon enhances antibody-dependent cellular cytotoxicity when suboptimal concentrations of antibody are used. (1984) (34)
Functional Correlates of Insertion Mutations in the Protease Gene of Human Immunodeficiency Virus Type 1 Isolates from Patients (2001) (34)
Randomized trial of transfer factor treatment of human warts. (1975) (34)
Failure of short-term CD4-PE40 infusions to reduce virus load in human immunodeficiency virus-infected persons. (1994) (34)
Preliminary studies of acyclovir in chronic hepatitis B. (1982) (34)
Natural killer cells activity in patients with multiple sclerosis given α interferon (1983) (34)
An active interferon inducer obtained from Hemophilus influenzae type B. (1969) (33)
Hemolytic-uremic-like syndrome following polycarboxylate interferon induction. Treatment of Dawson's inclusion-body encephalitis. (1971) (33)
AIDS CLINICAL TRIALS GROUP 384 TEAM. COMPARISON OF FOUR-DRUG REGIMENS AND PAIRS OF SEQUENTIAL THREE-DRUG REGIMENS AS INITIAL THERAPY FOR HIV-1 INFECTION (2003) (33)
Induction of interferon by nonviral agents. (1970) (33)
Regulation of guinea-pig immune functions by interleukin 2: critical role of natural killer activity in acute HSV-2 genital infection. (1986) (33)
Plasma viremia in human immunodeficiency virus infection: relationship to stage of disease and antiviral treatment. (1992) (33)
Effects of interferon-alpha on human warts. (1982) (32)
Replication or Inactivation of Different Viruses by Human Lymphocyte Preparations (1974) (32)
Anti-HIV type 1 activity of 3'-fluoro-3'-deoxythymidine for several different multidrug-resistant mutants. (2001) (32)
Treatment of AIDS with combinations of antiretroviral agents. (1991) (31)
Zidovudine (AZT) reduces virus titer, retards immune dysfunction, and prolongs survival in the LP-BM5 murine induced immunodeficiency model. (1990) (31)
Quantitation of human immunodeficiency virus by culture and polymerase chain reaction in response to didanosine after long-term therapy with zidovudine. (1994) (31)
Native and recombinant herpes simplex virus type 1 envelope proteins induce human immune T-lymphocyte responses (1987) (30)
Genotypic and phenotypic changes during culture of a multinucleoside-resistant human immunodeficiency virus type 1 strain in the presence and absence of additional reverse transcriptase inhibitors (1996) (30)
Studies on the Toxicity and Antiviral Activity of Various Polynucleotides (1973) (30)
Role of interferon in prophylaxis of rabies after exposure. (1976) (30)
Regulation by recombinant interleukin-2 of protective immunity against recurrent herpes simplex virus type 2 genital infection in guinea pigs (1987) (30)
Antiviral agents and human viral diseases. (1997) (30)
Ganciclovir treatment of cytomegalovirus infections in iatrogenically immunocompromised patients. (1987) (30)
Acute genital infection in guinea pigs: effect of recombinant interleukin-2 on herpes simplex virus type 2. (1986) (30)
Deficiency in antibody response to human cytomegalovirus glycoprotein gH in human immunodeficiency virus-infected patients at risk for cytomegalovirus retinitis. (1994) (30)
Hydroxyurea Enhances the Activities of Didanosine, 9-[2-(Phosphonylmethoxy)ethyl]adenine, and 9-[2-(Phosphonylmethoxy)propyl]adenine against Drug-Susceptible and Drug-Resistant Human Immunodeficiency Virus Isolates (1999) (29)
Immunoregulation by gamma-interferon? (1982) (29)
Human cytomegalovirus glycoprotein-receptor interactions. (1991) (29)
Zidovudine (azido dideoxythymidine) inhibits characteristic early alterations of lymphoid cell populations in retrovirus-induced murine AIDS. (1990) (29)
Alternating and intermittent regimens of zidovudine (3'-azido-3'-deoxythymidine) and dideoxycytidine (2',3'-dideoxycytidine) in the treatment of patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. (1990) (28)
Type I and type II interferons: differential antiviral actions in transformed cells. (1980) (27)
Human immunodeficiency virus reverse transcriptase codon 215 mutations diminish virologic response to didanosine-zidovudine therapy in subjects with non-syncytium-inducing phenotype. (1996) (27)
Genotypic, Phenotypic, and Modeling Studies of a Deletion in the β3-β4 Region of the Human Immunodeficiency Virus Type 1 Reverse Transcriptase Gene That Is Associated with Resistance to Nucleoside Reverse Transcriptase Inhibitors (2000) (27)
HIV-1 protease variants from 100-fold drug resistant clinical isolates: expression, purification, and crystallization. (2003) (26)
A REGULATORY ROLE FOR INTERFERON IN IMMUNITY * (1979) (26)
Recombinant HIV structural proteins detect specific cellular immunity in vitro in infected individuals. (1988) (26)
Highly active antiretroviral therapy results in HIV type 1 suppression in lymph nodes, increased pools of naive T cells, decreased pools of activated T cells, and diminished frequencies of peripheral activated HIV type 1-specific CD8+ T cells. (2000) (25)
Serial immunological studies in multiple sclerosis patients treated systemically with human alpha interferon (1985) (25)
Recombinant fibroblast interferon and immune interferon for treating chronic hepatitis B virus infection: patients' tolerance and the effect on viral markers. (1988) (25)
The prognostic significance of serum viral load, codon 215 reverse transcriptase mutation and CD4+ T cells on progression of HIV disease in a double-blind study of thymopentin (1996) (25)
Effect of interferon on TRIC agents and induction of interferon by TRIC agents. (1967) (25)
Genotypic and phenotypic analysis of a novel 15-base insertion occurring between codons 69 and 70 of HIV type 1 reverse transcriptase. (2002) (24)
Peripheral blood mononuclear cell human immunodeficiency virus type 1 proviral DNA quantification by polymerase chain reaction: relationship to immunodeficiency and drug effect (1993) (24)
Studies on the antiviral activity and cell interaction of synthetic double-stranded polyribo- and polydeoxyribonucleotides. (1972) (24)
Cytomegalovirus: where have we been and where are we going? (1990) (24)
The antiviral activity of certain thiophosphate and 2'-chloro substituted polynucleotide homopolymer duplexes. (1972) (24)
Synergistic antitumor activity with IFN and monoclonal anti-idiotype for murine B cell lymphoma. Mechanism of action. (1988) (24)
Effect of Crude and Purified Interferons on the Growth of Uninfected Cells in Culture.∗ (1966) (24)
Increasing Prevalence of HIV-1 Reverse Transcriptase Mutation K65R Correlates with Tenofovir Utilization (2004) (23)
Interferons as cell growth inhibitors and antitumor factors (1986) (23)
Significance of local gamma interferon in recurrent herpes simplex infection. (1986) (23)
Interferon stimulated by Double Stranded RNA (1970) (22)
HIV type 1 genotypic resistance in a clinical database correlates with antiretroviral utilization. (2004) (22)
Factors affecting the interferon sensitivity of human cytomegalovirus. (1978) (22)
A technique for the specific cleavage of arginyl bonds by trypsin (1962) (22)
Allogeneic dendritic cell induction of HIV-specific cytotoxic T lymphocyte responses from T cells of HIV type 1-infected and uninfected individuals. (1997) (22)
Detection and quantification of gene amplification products by a nonisotopic automated system. (1992) (22)
Varicella zoster virus: interferon production and comparative interferon sensitivity in human cell cultures. (1971) (21)
Interferon gamma production by herpes simplex virus antigen-specific T cell clones from patients with recurrent herpes labialis. (1985) (21)
Generation of primary peptide-specific CD8+ cytotoxic T-lymphocytes in vitro using allogeneic dendritic cells. (1998) (21)
Stimulation or inhibition of interferon production depending on time of cycloheximide administration. (1970) (20)
Effect of therapeutic immunization with recombinant gp160 HIV-1 vaccine on HIV-1 proviral DNA and plasma RNA: relationship to cellular immune responses. (1997) (20)
Different Molecular Species of Mouse Interferon Induced by Statolon (1965) (20)
Potentiating Effect of Freund's Adjuvant on Interferon Production by Endotoxin or Poly rI•Poly rC (1970) (19)
Drug resistance and heterogeneous long-term virologic responses of human immunodeficiency virus type 1-infected subjects to zidovudine and didanosine combination therapy. The AIDS Clinical Trials Group 143 Virology Team. (1995) (19)
Quantitative RNA and DNA gene amplification can rapidly monitor HIV infection and antiviral activity in cell cultures. (1992) (19)
Inactivation of S-adenosylhomocysteine hydrolase during adenine arabinoside therapy. (1982) (19)
Inverse relationship of CD8+CD11+ suppressor T cells with human immunodeficiency virus (HIV)-specific cellular cytotoxicity and natural killer cell activity in HIV infection. (1991) (19)
Role of preimmunization virus sequences in cellular immunity in HIV-infected patients during HIV type 1 MN recombinant gp160 immunization. (1998) (19)
Interleukin-2 in the treatment of HIV disease (1990) (18)
Effect of Separate and Combined Injections of Poly rI: Poly rC and Endotoxin on Reticulo-endothelial Activity, Interferon, and Antibody Production in the Mouse (1971) (18)
Granulocyte-macrophage colony-stimulating factor induces modest increases in plasma human immunodeficiency virus (HIV) type 1 RNA levels and CD4+ lymphocyte counts in patients with uncontrolled HIV infection. (2003) (18)
Clinical Trial of Natural Alpha Interferon in Multiple Sclerosis a (1984) (18)
Reciprocal changes in interferon production and immune responses of mouse spleen cells fractionated over columns of insolubilized conjugates of histamine. (1977) (18)
The importance of G0 in the site of action of interferon in the cell cycle. (1981) (17)
Modified skin lesions during concurrent varicella and measles infections. (1968) (17)
Interferon prophylaxis against simian varicella in Erythrocebus patas monkeys. (1983) (17)
Zidovudine susceptibility testing of human immunodeficiency virus type 1 (HIV) clinical isolates. (1993) (17)
Antiviral activity of the human immunodeficiency virus type 1-specific nonnucleoside reverse transcriptase inhibitor HBY 097 alone and in combination with zidovudine in a phase II study. HBY 097/2001 Study Group. (1999) (17)
Evaluation of the antiviral effect of rifabutin in AIDS-related complex. (1989) (17)
The role of HLA-DR determinants in monocyte-macrophage presentation of herpes simplex virus antigen to human T cells. (1981) (17)
Large-scale serological screening for cytomegalovirus antibodies in homosexual males by enzyme-linked immunosorbent assay (1984) (16)
Human cytomegalovirus DNA is present in CD45+ cells in semen from human immunodeficiency virus-infected patients. (1995) (16)
Enhancement of host defense mechanisms by pharmacological agents. (1975) (16)
Assessment of the antigenic response in humans to a recombinant mutant interferon beta (1987) (16)
Clinical Utilization of Exogenous Human Interferon (1975) (16)
Multiplicity-dependent replication of varicella-zoster virus in interferon-treated cells. (1977) (15)
Intermittent, alternating, and concurrent regimens of zidovudine and 2'-3' dideoxycytidine in the LP-BM5 murine induced immunodeficiency model. (1991) (15)
Interferon induction by and ribonuclease sensitivity of thiophosphate-substituted polyribonucleotides. (1969) (15)
Cat interferon inhibits feline leukaemia virus infection in cell culture. (1972) (15)
Hepatitis B‐associated membranous glomerulonephritis treated with adenine arabinoside monophosphate (1986) (15)
Zidovudine resistance reverse transcriptase mutations during didanosine monotherapy. (1996) (15)
The AIDS Clinical Trials Group (1990) (15)
Interferon clearance rate decreased after repeated injections. (1971) (15)
Individualization of therapy using viral markers. (1995) (15)
Two Mechanisms of Cell Resistance to Repeated Stimulation of Interferon 1 (1970) (15)
INTERFERON IN CHRONIC HEPATITIS B INFECTION (1980) (15)
Immunological complications in multiple sclerosis patients receiving interferon (1985) (15)
Lymph node human immunodeficiency virus RNA levels and resistance mutations in patients receiving high-dose saquinavir. (1998) (14)
Association of a Novel Human Immunodeficiency Virus Type 1 Protease Substrate Cleft Mutation, L23I, with Protease Inhibitor Therapy and In Vitro Drug Resistance (2004) (14)
Progressive multifocal leukoencephalopathy: clinical pathological correlates and failure of a drug trial in two patients. (1976) (14)
Preliminary trial of recombinant fibroblast interferon in chronic hepatitis B virus infection (1986) (14)
STUDIES ON THE ANTIGENIC COMBINING SITES IN BACTERIOPHAGE LYSOZYME (1963) (14)
Pharmacokinetics of Nelfinavir and Efavirenz in Antiretroviral-Naïve, Human Immunodeficiency Virus-Infected Subjects when Administered Alone or in Combination with Nucleoside Analog Reverse Transcriptase Inhibitors (2005) (13)
Interferon-the first quarter century. (1982) (13)
Natural killer cell activity in patients with multiple sclerosis given alpha interferon. (1983) (13)
Synthesis of Viral-Specific Ribonucleic Acid in Rubella Virus-Infected Cells (1969) (13)
Polyethylene glycol-modified interleukin-2 and thymosin alpha 1 in human immunodeficiency virus type 1 infection. (1996) (13)
The essential role of specific conformation in the antigenicity of ribonuclease. (1966) (13)
The effect of bursectomy and thymectomy on the course of avian influenza virus infection. (1973) (13)
Nonviral Interferon Inducers (1970) (13)
Use of intravenous immune globulin in patients receiving bone marrow transplants (1982) (12)
Comparison of combinations of interferons with tumor specific and nonspecific monoclonal antibodies as therapy for murine B- and T-cell lymphomas. (1988) (12)
Physical and biological characterization of antigen presenting liposome formulations: relative efficacy for the treatment of recurrent genital HSV-2 in guinea pigs. (1990) (12)
Decreased interferon synthesis and responsiveness to interferon by leukocytes from multiple sclerosis patients given natural alpha interferon. (1984) (12)
Safety and Efficacy of Autologous CD34+ Hematopoietic Progenitor Cells Transduced with an Anti-Tat Ribozyme in a Multi-Center, Randomized, Placebo-Controlled, Phase II Gene Therapy Trial for the Human Immunodeficiency Virus (2009) (12)
In Vivo Persistence of Donor Cells following Adoptive Transfer of Allogeneic Dendritic Cells in HIV-Infected Patients (2000) (12)
Interferon's promise in clinical medicine. Fact or fancy? (1967) (12)
Experience with clinical applications of interferon and interferon inducers (1978) (12)
A novel approach to assessing the drug susceptibility and replication of human immunodeficiency virus type 1 isolates. (1997) (12)
Enhanced in vivo therapeutic response to interferon in mice with an in vitro interferon-resistant B-cell lymphoma. (1989) (11)
Wide Open 1.3A Structure of a Multi-drug Resistant HIV-1 Protease Represents a Novel Drug Target (2005) (11)
Influence of increasing 2'-O-methylation on the interferon stimulating capacity of poly(rl)-poly(rC). (1974) (11)
Relationship of HIV-1 provirus load, CD8+ CD11+ T cells and HIV-1 envelope-specific cytotoxic T lymphocytes in HIV-infected asymptomatic offients. (1994) (11)
Thermal activation of the antiviral activity of synthetic polyribonucleotides: influence of DEAE-dextran in various cell cultures (1971) (11)
Beta interferon produced by keratinocytes in human cutaneous infection with herpes simplex virus. (1987) (11)
Resistance mutations to zidovudine and saquinavir in patients receiving zidovudine plus saquinavir or zidovudine and zalcitabine plus saquinavir in AIDS clinical trials group 229. (1999) (10)
Effect of interferon therapy on circulating lymphocytes in humans. (1980) (10)
Alpha interferon administration to infants with congenital rubella (1982) (10)
Uncertain role of cytosine arabinoside in varicella infection of compromised hosts. (1972) (10)
Exfoliative cytology in the evaluation of interferon treatment of cervical intraepithelial neoplasia. (1984) (10)
Simultaneous Viral and Non-Viral Interferon Production in Human Cell Cultures 1 (1970) (10)
UCLA conference. Interferon: immunobiology and clinical significance. (1982) (10)
Comparison of antiviral activities of cloned and native human interferons against herpes simplex virus types 1 and 2 and human cytomegalovirus (1984) (10)
Antivirals with clinical potential (1976) (9)
Effect of therapeutic immunization with HIV type 1 recombinant glycoprotein 160 ImmunoAG vaccine in HIV-infected individuals with CD4+ T cell counts of >or=500 and 200-400/mm3 (AIDS Clinical Trials Group Study 246/946). (2001) (9)
The role of interferon in viral infections (1979) (9)
Various molecular species of interferon induced by viral and nonviral agents. (1967) (9)
Continuous presence of CD4-PE40 is required for antiviral activity against single-passage HIV isolates and infected peripheral blood mononuclear cells. (1993) (9)
Phase I study of human leukocyte interferon in patients with advanced cancer. (1983) (8)
Perspectives for the control of cytomegalovirus infections in bone marrow transplant recipients. (1978) (8)
Therapeutic approaches to chronic hepatitis B. (1982) (8)
Delayed-type hypersensitivity to recombinant HIV envelope glycoprotein (rgp160) after immunization with homologous antigen. (1999) (8)
Pharmacokinetics of zidovudine alone and in combination with oxazepam in the HIV infected patient. (1993) (8)
Resistance to Interferon-α in a Mouse B-Cell Lymphoma Involves DNA Methylation (1992) (8)
Antiviral activity and dose optimum of recombinant macrophage colony-stimulating factor on herpes simplex genitalis in guinea pigs. (1991) (8)
Human immunodeficiency virus envelope glycoproteins. (1994) (8)
Molecular species of circulating interferon in mice injected with Newcastle disease virus. (1968) (8)
Virology and immune mechanisms (1981) (8)
Structure and Infectivity of Picornaviral RNA Encapsidated by Cowpea Chlorotic Mottle Virus Protein (1973) (7)
Quantitative analysis of syncytium-inducing and non-syncytium-inducing virus in patients infected with human immunodeficiency virus type 1 (1995) (7)
T Cell Activation Markers and African Mitochondrial DNA Haplogroups among Non-Hispanic Black Participants in AIDS Clinical Trials Group Study 384 (2012) (7)
Zidovudine and dideoxycytidine differ in their effects on human immunodeficiency virus-induced pathologic activation of the immune system. AIDS Clinical Trial Research Group 047. (1994) (7)
Human immunodeficiency virus type 1 infection in Oman: antiretroviral therapy and frequencies of drug resistance mutations. (2004) (7)
The lact of antiviral effect of (polyinosinic acid): (polycytidylic acid) when attached to insoluble supports. (1975) (7)
In Vitro HIV-1 Evolution in Response to Triple Reverse Transcriptase Inhibitors & In Silico Phenotypic Analysis (2013) (7)
Approaches to the control of viral infections in man. (1971) (7)
Results of Early-Phase Studies in Patients with Acquired Immunodeficiency Syndrome (AIDS) or Advanced AIDS-Related Complex (1990) (7)
New two-amino acid insertion near codon 70 of the HIV type 1 protease gene. (2005) (7)
Interferon production by individual cells. (1974) (7)
Disposition of antigen-presenting liposomes in vivo: effect on presentation of herpes simplex virus antigen rgD. (1994) (6)
What are we going to do about AIDS and HTLV-III/LAV infection? (1984) (6)
Interferon--1968. How much do we understand? (1968) (6)
Nonnucleoside Reverse Transcriptase Inhibitor Phenotypic Hypersusceptibility Can Be Demonstrated in Different Assays (2005) (6)
Is Recombinant Interleukin-2 the Best Way to Deliver Interferon-γ in Human Disease? (1987) (6)
Use of PCR to measure HIV viral changes in drug-resistant genes in genital fluids. (1998) (6)
Interferon and its inducers: antiviral and other effects. (1972) (6)
HIV Resistance to Dideoxynucleoside Inhibitors (1993) (6)
HIV virology for clinical trials. (1995) (6)
New virologic tools for the design and analysis of clinical trials. (1995) (6)
Correlation of single photon emission computed tomography parameters as a noninvasive alternative to liver biopsies in assessing liver involvement in the setting of HIV and hepatitis C virus coinfection: a multicenter trial of the Adult AIDS Clinical Trials Group. (2003) (6)
From the National Institute of Allergy and Infectious Diseases. Report on a workshop on DNA recombinant technology in interferon cloning. (1981) (6)
Antivirals with clinical potential. Introduction. (1976) (5)
Inhibition of Multiplication of Mycobacterium leprae by Polyinosinic-Polycytidylic Acid (1977) (5)
Safety, pharmacokinetics, and antiviral response of CD4-immunoglobulin G by intravenous bolus in AIDS and AIDS-related complex. (1995) (5)
Symposium on interferon and host response to virus infection. Introduction. (1970) (5)
Phase I evaluation of a synthetic mutant of beta-interferon. (1985) (5)
Rare One and Two Amino Acid Inserts Adjacent to Codon 103 of the HIV-1 Reverse Transcriptase (Rt) Affect Susceptibility to Non-Nucleoside Rt Inhibitors (2005) (5)
A Rapid Phenotypic Assay for Detecting Multiple Nucleoside Analogue Reverse Transcriptase Inhibitor-Resistant HIV-1 in Plasma (2002) (5)
Antiviral agents and viral diseases of man. 3rd edition. (1990) (5)
Long-term effects of interleukin-2 on CD4 cell counts in human immunodeficiency virus-infected patients. (1994) (5)
Molecular Requirements for Synthetic RNA to Act in Interferon Stimulation (1971) (5)
Heterogeneity of cytokine functions in HIV infection (1997) (4)
Relation of the pathogenesis of human immunodeficiency virus infection to various strategies for its control. (1991) (4)
A Second Molecular Species of Mouse Interferon in Mice injected with Statolon (1966) (4)
Effect of interferon on the replication of Sendai virus. (1970) (4)
Virus–Lymphocyte Interactions (1971) (4)
Infectious Diseases Society of America. Trials of interferon therapy for multiple sclerosis. (1982) (4)
Distribution of CMV Glycoprotein UL55 (gB) and UL75 (gH) Sequence Variant Groups in Patients Infected with HIV (1995) (4)
Herpes zoster: recent studies. (1973) (4)
Effect of Cytosine Arabinoside on Disseminated Herpes Zoster and Vesicle Fluid Interferon. (1972) (3)
Cytomegalovirus-specific cell-mediated immune responses in heart and heart-lung transplant recipients are not predictive for the occurrence of symptomatic CMV disease or tissue rejection. (1991) (3)
Persistence versus Reversion of 3TC Resistance in HIV-1 Determine the Rate of Emergence of NVP Resistance (2012) (3)
Failure of an Interferon Inducer to Inhibit Multiplication of Mycobacterium leprae 1 (1970) (3)
Interferon: its inducers and some aspects of host resistance in malignancy. (1974) (3)
Advances in interferon research - Medical Staff Conference. (1982) (3)
4.3 The laboratory in managing HIV infection (1996) (3)
Role of macrophage D-region antigens and T-lymphocyte differentiation antigens in induction of gamma interferon. (1985) (3)
In Vivo Release of Previously Cleared Interferon by Cycloheximide (1972) (3)
Treatment of cytomegalovirus infection in the AIDS patient. (1991) (3)
Is recombinant interleukin-2 the best way to deliver interferon-gamma in human disease? (1987) (3)
Therapy of HIV-1 infection (1994) (3)
INHIBITION OF LYMPHOMA HYBRIDS BY HUMAN INTERFERON (1980) (3)
In vivo persistence of donor cells following adoptive transfer of allogeneic dendritic cells in HIV-infected patients. (2000) (2)
Success of Antiviral Therapy Involves Cooperative Immune Responses (1979) (2)
Resistance to interferon-alpha in a mouse B-cell lymphoma involves DNA methylation. (1992) (2)
Interferon and Interferon Inducers: The Clinical Outlook (1969) (2)
A personal view of efforts in treatment of human immunodeficiency virus infection in 1988. (1989) (2)
'Non-specific' mediators in host defense against respiratory viruses: assay methods and results. (1975) (2)
Interferon: An Immune-Specific or a Non-Specific Host Defense?1 (1973) (2)
Antiviral therapy in hepatitis B infection (1978) (2)
Infections With Cytomegalovirus in Adults and the Natural History and Treatment of Cytomegalovirus Retinitis (1981) (2)
CD8+ CD11+ suppressor cells in HIV-infected asymptomatic patients: effect on HIV-specific cytotoxicity. (1992) (2)
Virology and immune mechanisms. (1981) (1)
Summary of the Symposium (1990) (1)
High-performance liquid chromatographic analysis of hypoxanthine arabinoside in plasma. (1984) (1)
Interferons as antivirals in man. (1982) (1)
Impact of prophylactic immediate post-transplant genciclovir on development of transplant atherosclerosis: A randomized placebo-controlled study (1996) (1)
Generation of Primary Peptide-Specific Cd8+ Cytotoxic T-lymphocytes in Vitro using allogeneic dendritic cells (1998) (1)
The Use of Interferons in the Control of Viral Diseases (1984) (1)
Treatment of cytomegalovirus infection with intravenous ARA-A (1978) (1)
ALPHA-INTERFERON IN SIMIAN AND HUMAN VARICELLA (1982) (1)
Comparison ofAntiviral Activities ofClonedandNative Human Interferons Against HerpesSimplex VirusTypes1and2andHuman Cytomegalovirus (1984) (1)
Acute delta hepatitis during treatment with adenosine arabinoside monophosphate with resolution of the HBsAg carrier state. (1990) (1)
Cellular immunity to herpes simplex infection in humans. (1976) (1)
Cytomegalovirus infection in heart transplant recipients: Preliminary results of a controlled trial of intravenous gamma globulin (1982) (1)
Systemic antivirals for therapy of herpesvirus diseases. (1982) (1)
HIV-1 Evolution in Response to Triple Reverse Transcriptase Inhibitor Induced Selective Pressure in vitro (2013) (0)
Pharmacokinetics of Nelﬁnavir and Efavirenz in Antiretroviral-Naı¨ve, Human Immunodeﬁciency Virus-Infected Subjects when Administered Alone or in Combination with Nucleoside Analog Reverse Transcriptase Inhibitors (2005) (0)
Combination Anti-HIV Therapy: Questions and Answers (1993) (0)
Short-Course HumanLeukocyte Interferon inTreatment of Herpes Zoster inPatients withCancer (1981) (0)
Stanford study of Sézary syndrome (1983) (0)
Crystal structures of a Multidrug-Resistant HIV-1 Protease Reveal an Expanded Active Site Cavity (2004) (0)
Survival in Chronic Hepatitis B (2020) (0)
Quantification of Human Cytomegalovirus DNA during Viremia identifies Risk for Retinitis in AIDS Patients (1996) (0)
Interferon Induction in Mouse and Man with Viral and Non‐Viral Stimuli (2008) (0)
Rapid Publication Reduction in Plasma Human Immunodeficiency Virus Ribonucleic Acid after Dideoxynucleoside Therapy as Determined by the Polymerase Chain Reaction (2013) (0)
Viral diseases in developing countries. (1988) (0)
Lymphocyte transformation and interferon production as measures of cellular immunity in lymphoma patients. (1978) (0)
[Evaluation of teleroentgenography in the surgical and orthodontical treatment of prognathism]. (1972) (0)
The Use of Peptide/MHC Tetramers to Visualize, Track, and Characterize Class I‐Restricted Anti‐HIV T‐Cell Responses (2001) (0)
In Remembrance of LOWELL GLASGOW, M.D. (1982) (0)
CLOSING REMARKS (1980) (0)
Interfering with cancer (1975) (0)
Structural requirements for interferon induction by poly anions (1969) (0)
Condom usage reported by female sexual partners of asymptomatic HIV seropositive hemophilic men. (1989) (0)
Murine monoclonal antibody to a si infectivity of human cytomegaloviri (2016) (0)
Zidovudine resistance of human immunodeficiency virus. Discussion (1990) (0)
Lamivudine-resistant HIV Type 1 Clinical Isolates Under Lamivudine Pressure Show Impaired Selection of Resistance to Nonnucleoside Reverse Transcriptase Inhibitors (0)
Clinical testing of human interferon in infectious diseases. (1974) (0)
Clinical virology, interferon, and infectious diseases in the People's Republic of China in 1979. (1980) (0)
Translating clinical trials to clinical practice : satellite symposium to the 2nd International Congress on Drug Therapy in HIV Infection, 29 November 1994, Glasgow, Scotland (1996) (0)
Virus infections. (1976) (0)
Systemic Application of Antivirals for Herpes Infections (1981) (0)
Studies on theToxicity andAntiviral Activity of (1973) (0)
Clinical trials of combination therapies for HIV infection. Discussion. (1990) (0)
Introduction and Dedication (1976) (0)
Clinical experience with antivirals (1984) (0)
The Safety and Efficacy of Zidovudine (AZT) in the Treatment of Subjects with Mildly Symptomatic Human Immunodeficiency Virus Type 1 (HIV) Infection (2020) (0)
Interferon as an anti-viral (1977) (0)
PLASMA FIBRINOLYSIS IN MAN: T H E EFFECT OF CHY'LOMICRONS DERIVED FROM D I F F E R E N T DIETARY FATS* (2003) (0)
Clarification of a method to reverse transcribe human immunodeficiency virus RNA. (1995) (0)
Interferon redux (1982) (0)
Role of Physician-Scientists in the Control of Human Immunodeficiency Virus. (2018) (0)
ndomized Study of Didanosine Monotherapy and Combination Therapy With Zidovudine in Hemophilic and Nonhemophilic Subjects With Asymptomatic Human Immunodeficiency Virus-l Infection (2002) (0)
Cytomegalovirus Retinitis in Immunosuppressed Hosts (2020) (0)
Inhibition of radiation-induced lymphoma development in mice by inter- feron. Abstr. (1971) (0)
Natural polymorphism of HIV-1 clade B protease gene and implications for therapy (1995) (0)

This paper list is powered by the following services:

Other Resources About Thomas C. Merigan

en.wikipedia.org

What Schools Are Affiliated With Thomas C. Merigan?

Thomas C. Merigan is affiliated with the following schools:

Thomas C. Merigan's Academic­Influence.com Rankings